Poseidon Investment Management

Poseidon Investment Management

Poseidon Investment Management set up in 2013, co-headquartered in Berlin and San Francisco, and began deploying capital into the legal cannabis and industrial-hemp supply chains the following year. The firm describes itself as the pioneer cannabis hedge fund, making it among the earliest dedicated pools of institutional capital to target plant-touching operators at a time when most allocators treated the sector as uninvestable. From the start, Poseidon committed to a mandate that excluded ancillary picks in favor of companies that physically cultivate, process, distribute, or brand cannabis and hemp products. The firm pursues a long/short equity strategy across the full value chain, combining public-market positions with private, late-stage venture placements. The portfolio spans North American multistate operators, European licensed producers, pharmaceutical-facing cannabinoid developers, and branded consumer packaged goods. Poseidon has sourced deal flow at the intersection of regulatory liberalization and consumer adoption, taking concentrated stakes in cultivation, extraction, retail, and infused-product verticals. Geographic exposure centers on the US, Canada, and Germany, with the firm monitoring emerging regulatory frameworks in Latin America and the EU for second-wave entry points. The fund maintains a deliberately lean structure, operating from dual hubs that reflect the two largest federal legalization events of the 2010s: Colorado and Washington State in the US, and Germany’s medical-cannabis framework in 2017. No outside investment vehicles, philanthropic foundations, or co-investor clubs are disclosed under the Poseidon banner. In May 2024: The firm refreshed its public digital footprint, relaunching poseidon.partners as a focused domain that restates its original 2014 vintage and plant-touching-only thesis. Poseidon’s architecture differs from the wave of cannabis venture funds that followed by preserving a public-markets core alongside private allocations — a structure that allows it to express short views in an industry where bankruptcies, license revocations, and regulatory swings create asymmetric downside. That dual capability, paired with a geographic split anchored in the two largest federally regulated cannabis markets, shapes a posture distinct from both US-only venture boutiques and broad-spectrum life-sciences funds that treat cannabinoids as a side allocation.